Immunome Inc [IMNM] stock is trading at $9.85, up 9.57%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The IMNM shares have gain 1.76% over the last week, with a monthly amount drifted -1.70%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Immunome Inc [NASDAQ: IMNM] stock has seen the most recent analyst activity on September 05, 2025, when Craig Hallum initiated its Buy rating and assigned the stock a price target of $26. Previously, Lake Street started tracking the stock with Buy rating on April 02, 2025, and set its price target to $23. On November 08, 2024, Stephens initiated with a Overweight rating and assigned a price target of $30 on the stock. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $27 on May 31, 2024. JP Morgan initiated its recommendation with a Overweight and recommended $24 as its price target on April 30, 2024. Guggenheim started tracking with a Buy rating for this stock on April 15, 2024, and assigned it a price target of $35. In a note dated January 29, 2024, Leerink Partners initiated an Outperform rating and provided a target price of $30 on this stock.
Immunome Inc [IMNM] stock has fluctuated between $5.15 and $16.55 over the past year. Currently, Wall Street analysts expect the stock to reach $22 within the next 12 months. Immunome Inc [NASDAQ: IMNM] shares were valued at $9.85 at the most recent close of the market. An investor can expect a potential return of 123.35% based on the average IMNM price forecast.
Analyzing the IMNM fundamentals
Immunome Inc [NASDAQ:IMNM] reported sales of 12.59M for the trailing twelve months, which represents a growth of 69.84%. Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -17.84%, Pretax Profit Margin comes in at -16.87%, and Net Profit Margin reading is -16.87%. To continue investigating profitability, this company’s Return on Assets is posted at -0.72, Equity is -0.87 and Total Capital is -0.82. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.02.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Immunome Inc’s Current Ratio is 12.13. As well, the Quick Ratio is 12.13, while the Cash Ratio is 6.29. Considering the valuation of this stock, the price to sales ratio is 68.10, the price to book ratio is 3.18.
Transactions by insiders
Recent insider trading involved BIENAIME JEAN JACQUES, Director, that happened on Jun 03 ’25 when 5000.0 shares were purchased. Director, BIENAIME JEAN JACQUES completed a deal on Mar 25 ’25 to buy 7800.0 shares. Meanwhile, President and CEO SIEGALL CLAY B bought 0.14 million shares on Mar 26 ’25.
